(Press-News.org) (Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) – Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.
Despite complete surgical resection (R0), early-stage NSCLC carries a substantial risk of recurrence and remains a leading cause of cancer-related mortality.
The study, presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC), is the first randomized Phase III trial to examine chemo-immunotherapy in the adjuvant setting, building on perioperative evidence from the earlier NADIM and NADIM II studies.
Between January 2021 and December 2022, 206 patients from 30 hospitals across Spain were randomized 1:1 to receive either adjuvant chemotherapy (carboplatin AUC5 plus paclitaxel 200 mg/m² every 3 weeks for 4 cycles) followed by observation (control arm) or the same chemotherapy plus nivolumab 360 mg every 3 weeks for 4 cycles, followed by maintenance nivolumab 480 mg every 4 weeks for 6 cycles (experimental arm). The primary endpoint was disease-free survival (DFS); secondary endpoints included overall survival (OS) and safety. Minimal residual disease (MRD) was assessed using circulating tumor DNA (Guardant Reveal).
Mariano Provencio, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, reported that median DFS was not reached in either arm after a median follow-up of 34 months and the DFS first quartile was 30.98 months (experimental) vs. 17.01 months (control). The three-year relapse rate was 26.7% (experimental) vs. 40.1% (control).
Dr. Provencio also reported that the postoperative MRD associated with significantly worse DFS in the experimental arm (HR = 5.7, p = 0.045) and grade ≥3 treatment-related adverse events: 26.2% (experimental) vs. 14.5% (control) during adjuvant phase.
“The interim results of NADIM ADJUVANT suggest that adding nivolumab to adjuvant chemotherapy can reduce recurrence risk and may offer meaningful clinical benefit for patients with completely resected stage IB–IIIA NSCLC,” said Mariano Provencio, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda. “Further follow-up will be essential to confirm long-term efficacy.”
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.
END
NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC
Clinical trial included 206 patients from 30 hospitals in Spain
2025-09-08
ELSE PRESS RELEASES FROM THIS DATE:
EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC
2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) — Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation durvalumab alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
Consolidation durvalumab improves survival ...
Training to improve memory
2025-09-08
In Europe, almost one in 10 people over 70 suffers from dementia, and this figure could even triple by 2050 due to rising life expectancy. Over time, those affected lose everything that makes them who they are, including their memory and their ability to go about their everyday lives. Many also suffer from physical deterioration. In an advanced stage of the disorder, dementia patients generally require comprehensive care.
Now, the first drugs have emerged that can slightly slow down disease progression in the early stages of Alzheimer’s – ...
Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?
2025-09-08
New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Pain management is essential during cancer care, but prescription opioid practices associated with cancer treatment may lead to unsafe long-term opioid use and adverse outcomes such as opioid use disorder and opioid overdose. To assess the ...
Black youth, especially Black girls, use mental health services less than their White peers
2025-09-08
Black adolescents with mental distress are less likely to use mental health services than their White peers, and Black girls are the least likely to access care, according to new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241733.
“Adolescence is a crucial developmental stage and a critical period for onset of mental health problems,” writes Mercedes Sobers, a PhD candidate in epidemiology at the Dalla Lana School of Public Health, University of Toronto and research coordinator at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, ...
Canada must protect youth from sports betting advertising
2025-09-08
Canada must enact strong, effective legislation to protect youth from gambling advertising. Minors are suffering harms from problem gambling despite age restrictions, argue authors in an editorial in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251227 .
Since 2021, ads for sports betting have saturated sports broadcasts, constantly viewed by children. Gambling is normalized as a natural part of spectatorship at a young age. Even before single-game sports betting was legalized, a 2019 survey of Canadian students in grades 7–12 found about 4% of students ...
First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer
2025-09-07
First-in-Human Trial Shows Promising Results for DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer
(Barcelona, Spain Sunday, September 7, 2025 at 4:45 PM CEST / UTC +2) — A first-in-human Phase 1 study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC).
The results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
According to the International Agency for Research on Cancer, ...
Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial
2025-09-07
(Barcelona, Spain. September 7, 2025 at 4:45 PM CEST / UTC +2 )--Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
New data from the Phase 2 IDeate-Lung01 trial in 137 patients who had received ≥1 prior line of platinum-based chemotherapy showed a confirmed objective response rate (ORR) of ...
Higher blood pressure in childhood linked to earlier death from heart disease in adulthood
2025-09-07
Research Highlights:
Children who had higher blood pressure at age 7 were more likely to die early from cardiovascular disease by their mid-50s. The risk was highest for children whose blood pressure measurements were in the top 10% for their age, sex and height.
Both elevated blood pressure (90-94th percentile) and hypertension (≥95th percentile) were linked with about a 40% to 50% higher risk of early cardiovascular death in adulthood.
Researchers said their findings show why it’s important to regularly check children’s blood pressure and to help them develop heart-healthy habits early that can help lower their ...
AI helped older adults report accurate blood pressure readings at home
2025-09-07
Research Highlights:
Use of an AI voice agent to prompt self-reported blood pressure readings helped to improve accuracy of blood pressure measures and patient outcomes in a group of majority ages 65 and older patients with high blood pressure.
The study’s findings demonstrate how integrating AI into care can help to improve home blood pressure monitoring and completion rates, which can lead to improved quality outcomes for patients.
Note: The study featured in this news release is a research abstract. Abstracts presented at the American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published ...
High blood pressure in childhood and premature cardiovascular disease mortality
2025-09-07
About The Study: In a large sample of U.S. children born between 1959 and 1966, higher blood pressure (BP) at age 7 was associated with greater risk of premature cardiovascular disease (CVD) mortality. These findings build upon prior research that linked childhood systolic BP with fatal CVD in young adulthood, but that sample had a follow-up duration through a mean age of only 46 years. This study extends that work with follow-up into the mid-50s and demonstrated consistency in the magnitude of the associations within siblings, which mitigates concerns regarding unmeasured confounding due to shared family or lifestyle characteristics.
Corresponding ...
LAST 30 PRESS RELEASES:
Flavanols in cocoa can protect blood vessel function following uninterrupted sitting - study
$100 Million gift will advance UCSF’s dementia research and care
The 4th Japan-India Universities Forum on 15 November
Arctic town Kiruna is colder after the move
Mayo Clinic study finds majority of midlife women with menopause symptoms do not seek care
Underwater robot ‘Lassie’ discovers remarkable icefish nests during search for Shackleton’s lost ship off Antarctica
Wearable robots you can wear like clothes: automatic weaving of “fabric muscle” brings commercialization closer
Researcher improves century-old equation to predict movement of dangerous air pollutants.
Heatwaves linked to rise in sleep apnoea cases in Europe
Down‑top strategy engineered large‑scale fluorographene/PBO nanofibers composite papers with excellent wave‑transparent performance and thermal conductivity
The Lancet: Climate change inaction being paid for in millions of lives every year
New insights reveal how coral gets a grip
Home treatment with IV antibiotics could relieve NHS pressure
AI ECG better detects severe heart attacks in emergency setting
Straw-based biochar and smart irrigation help maize thrive with less water and fertilizer
‘Broken’ genes a common factor in marsupial fur colour
Turning waste into clean water: Magnetic carbon materials remove toxic pollutants from wastewater
World Health Organization’s priorities shaped by its reliance on grants from donor organisations such as the Gates Foundation
One in ten people without coeliac disease or wheat allergy report sensitivity to gluten or wheat
How can (A)I help you?
Study finds new system can cut patient waiting times for discharge
Allison Institute’s third annual scientific symposium highlighted by panel discussion with five Nobel laureates
SETI Institute accelerates the search for life beyond earth with NVIDIA IGX Thor
Wetlands efficiently remove nitrogen pollution from surface water, leading to cost savings for municipalities
Dr. Loren Miller presents oral late breaker at IDWeek 2025 of a first-of-its-kind clinical trial that shows efficacy of bacteriophage therapy for Staphylococcus aureus bacteremia
Dirty water boosts prospects for clean hydrogen
New multisociety guidance strengthens infection prevention and control in nursing homes
More scientific analysis needed on impacts of industrial decarbonization
New research uncovers how bad bacteria know where to cluster and cause infection
As ochre sea star ‘baby boomers’ grow up, species showing signs of recovery
[Press-News.org] NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLCClinical trial included 206 patients from 30 hospitals in Spain